Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
PPAR-alpha agonist (repurposed fibrate)

PLX-200

An investigational treatment for Krabbe Disease and Batten Disease.

Phase 2by Polaryx Therapeutics
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Drug facts

The same compound appears under different names depending on the context. Here is how to identify PLX-200 wherever you encounter it, plus the key facts at a glance.

Generic name
PLX-200
Development code
PLX-200
Drug class
PPAR-alpha agonist (repurposed fibrate)
Manufacturer
Polaryx Therapeutics
How it's taken
Liquid by mouth twice a day, in a trial only

An investigational liquid medicine taken by mouth from Polaryx Therapeutics, made from gemfibrozil, an older FDA-approved drug for very high triglycerides in adults[5][14].

  • Polaryx is testing it in children aged 2 to 15 with Krabbe disease, CLN2 or CLN3 Batten disease or Sandhoff disease in SOTERIA, an open-label Phase 2 trial that ClinicalTrials.gov lists as not yet recruiting[1].
  • Polaryx said on November 9, 2026 that its first US site had been activated to begin screening, and it has not reported any child dosed[4].
  • No results in people have been published, and it is not FDA approved for any of these diseases.
Follow PLX-200 by email

We'll email you when the FDA acts on PLX-200 and when new trials for the condition you pick open. Unsubscribe anytime.

You'll get, for Krabbe Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

How PLX-200 works

In Krabbe disease, changes in the GALC gene leave the body short of galactosylceramidase, an enzyme that works inside lysosomes, the cell's recycling compartments. Without it, a toxic fat called psychosine builds up and destroys myelin, the coating on nerve fibers[15]. PLX-200 is gemfibrozil, which switches on a receptor inside cells called PPAR-alpha[9].

Lab studies in brain cells found that gemfibrozil raises TFEB, a protein that turns on genes for building lysosomes, through PPAR-alpha[11], and an earlier study found it raised TPP1, the enzyme missing in CLN2 disease[12]. Polaryx says the drug also lowers inflammation and protects nerve cells from dying[9][8]. In the twitcher mouse, a model of Krabbe disease, Polaryx reports that the drug protected myelin, reduced activation of support cells in the brain, lengthened life and eased movement problems[8][7].

These are company animal results presented at a conference, not yet in a peer-reviewed paper, and whether any of this helps children with Krabbe disease is what SOTERIA is meant to start testing.

Clinical trial results

SOTERIA (NCT07740512) is an open-label, single-group Phase 2 basket trial, meaning one study with a separate group for each disease. It plans about 24 children aged 2 to 15 in all, split across Krabbe disease, CLN2 and CLN3 Batten disease and Sandhoff disease. The registry does not say how many places go to Krabbe disease, and its secondary measure describes the Krabbe group as late-infantile Krabbe disease.

Children need a genetically confirmed diagnosis, an age of symptom onset that fits the type being studied and the matching symptoms. Children who have ever had a stem cell transplant or gene therapy are excluded, whenever it happened. Also excluded are children who need breathing support other than CPAP or BiPAP during sleep, those with severe brain abnormalities such as a shunt, and those taking statins, repaglinide, dasabuvir, selexipag, pioglitazone or another fibrate.

Children with CLN2 disease who had Brineura need a 3-month break from it first, and children on miglustat a 2-week break[1]. The main measures are safety over the treatment period: side effects, serious side effects, lab tests, physical exams, vital signs and heart tracings (ECG) through week 102. Secondary measures include the Vineland Adaptive Behavior Scales, a caregiver interview about everyday skills, and caregivers' ratings of how severe the disease is[1].

Polaryx plans to compare the CLN2 and CLN3 groups with natural history records of untreated children, and it has not named a comparison group for the Krabbe group[8][6].

ClinicalTrials.gov lists no sites yet[1]. Polaryx said on November 9, 2026 that Boys Town National Research Hospital in Boys Town, Nebraska is its first activated site, positioned to begin screening, that 5 more US sites are expected by the end of the first quarter of 2027, and that applications to start the trial in the EU and UK were filed in October 2026[4]. The registry gives an estimated primary completion date of December 31, 2028 and a study completion date of February 1, 2029[1].

An earlier placebo-controlled Phase 3 study of PLX-200 in CLN3 disease (NCT04637282) never started. ClinicalTrials.gov lists it as withdrawn with 0 participants, saying the sponsor removed it to avoid further outreach from families because the study had not begun[2].

Main registered trial: NCT07740512 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.

Side effects and safety

Early trial safety observations

No safety results from PLX-200 in people with Krabbe disease, or any other disease, have been published, and Polaryx had reported no child dosed in SOTERIA as of November 9, 2026[4]. Since PLX-200 is gemfibrozil, the tablet label for adults with high triglycerides is the closest guide. That label carries no boxed warning. In the Helsinki Heart Study, indigestion affected 19.6% of adults on gemfibrozil against 11.9% on placebo, and stomach pain 9.8% against 5.6%.

Gallstones and gallbladder surgery were more common, and the label also lists muscle problems, which are more serious alongside statin drugs, as well as changes in liver tests and blood counts[14]. The label says safety and effectiveness in children have not been established[14]. A 2017 review written with Polaryx authors counted 200 children in published reports who took gemfibrozil for other conditions and found 3 with side effects, 2 with muscle pain and 1 with a skin reaction[13].

SOTERIA leaves out children with gallbladder disease, liver tests above 3 times normal, reduced kidney filtering, a serious heart rhythm problem or uncontrolled seizures, and children on warfarin need more frequent blood clotting tests to take part[1]. No clinical hold has been reported.

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking PLX-200

Taken by mouth as a liquid, twice a day about 12 hours apart, 30 minutes before the morning and evening meals[1]. In SOTERIA the dose is based on weight and raised over a 5-week titration period, followed by 96 weeks at the target dose, about 101 weeks in all[1]. Polaryx says it developed the liquid because many children with these diseases have trouble swallowing tablets[8]. The dose amounts have not been published.

Development history

Gemfibrozil has been sold for decades to lower blood fats in adults[14]. Academic lab work at Rush University, starting around 2012, linked it to lysosome activity in brain cells[12][11], and Polaryx develops it as PLX-200[13]. The FDA granted orphan drug designation for gemfibrozil in Krabbe disease to Polaryx on August 30, 2021[3]. Polaryx also announced FDA orphan designations in GM2 gangliosidoses, which include Sandhoff disease, in 2021[9], and in neuronal ceroid lipofuscinoses, as well as an EU orphan designation for neuronal ceroid lipofuscinosis in February 2018[10].

Polaryx says the FDA sent a safe-to-proceed letter for SOTERIA in October 2025[7], granted Fast Track designation for CLN2 disease in March 2026, and Polaryx announced on April 21, 2026 that the FDA had also granted it for Krabbe disease, CLN3 disease and Sandhoff disease[5]. Fast Track allows more frequent FDA meetings and is not a finding that a drug works. Polaryx has not announced a rare pediatric disease designation for Krabbe disease.

Ask anything about PLX-200
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Krabbe Disease and Batten Disease trials

Other Krabbe Disease & Batten Disease treatments

Common questions about PLX-200

▸What is PLX-200?

An investigational liquid medicine taken by mouth from Polaryx Therapeutics, made from gemfibrozil, an older FDA-approved drug for very high triglycerides in adults[5][14]. Polaryx is testing it in children aged 2 to 15 with Krabbe disease, CLN2 or CLN3 Batten disease or Sandhoff disease in SOTERIA, an open-label Phase 2 trial that ClinicalTrials.gov lists as not yet recruiting[1]. Polaryx said on November 9, 2026 that its first US site had been activated to begin screening, and it has not reported any child dosed[4]. No results in people have been published, and it is not FDA approved for any of these diseases.

▸How does PLX-200 work?

In Krabbe disease, changes in the GALC gene leave the body short of galactosylceramidase, an enzyme that works inside lysosomes, the cell's recycling compartments. Without it, a toxic fat called psychosine builds up and destroys myelin, the coating on nerve fibers[15]. PLX-200 is gemfibrozil, which switches on a receptor inside cells called PPAR-alpha[9]. Lab studies in brain cells found that gemfibrozil raises TFEB, a protein that turns on genes for building lysosomes, through PPAR-alpha[11], and an earlier study found it raised TPP1, the enzyme missing in CLN2 disease[12]. Polaryx says the drug also lowers inflammation and protects nerve cells from dying[9][8]. In the twitcher mouse, a model of Krabbe disease, Polaryx reports that the drug protected myelin, reduced activation of support cells in the brain, lengthened life and eased movement problems[8][7]. These are company animal results presented at a conference, not yet in a peer-reviewed paper, and whether any of this helps children with Krabbe disease is what SOTERIA is meant to start testing.

▸What are the side effects of PLX-200?

No safety results from PLX-200 in people with Krabbe disease, or any other disease, have been published, and Polaryx had reported no child dosed in SOTERIA as of November 9, 2026[4]. Since PLX-200 is gemfibrozil, the tablet label for adults with high triglycerides is the closest guide. That label carries no boxed warning. In the Helsinki Heart Study, indigestion affected 19.6% of adults on gemfibrozil against 11.9% on placebo, and stomach pain 9.8% against 5.6%. Gallstones and gallbladder surgery were more common, and the label also lists muscle problems, which are more serious alongside statin drugs, as well as changes in liver tests and blood counts[14]. The label says safety and effectiveness in children have not been established[14]. A 2017 review written with Polaryx authors counted 200 children in published reports who took gemfibrozil for other conditions and found 3 with side effects, 2 with muscle pain and 1 with a skin reaction[13]. SOTERIA leaves out children with gallbladder disease, liver tests above 3 times normal, reduced kidney filtering, a serious heart rhythm problem or uncontrolled seizures, and children on warfarin need more frequent blood clotting tests to take part[1]. No clinical hold has been reported.

▸How is PLX-200 taken?

Taken by mouth as a liquid, twice a day about 12 hours apart, 30 minutes before the morning and evening meals[1]. In SOTERIA the dose is based on weight and raised over a 5-week titration period, followed by 96 weeks at the target dose, about 101 weeks in all[1]. Polaryx says it developed the liquid because many children with these diseases have trouble swallowing tablets[8]. The dose amounts have not been published.

▸Is PLX-200 FDA approved?

PLX-200 is currently in phase 2 clinical trials for Krabbe Disease and Batten Disease. It has not yet received FDA approval.

▸Is PLX-200 approved for Krabbe disease?

No. PLX-200 is investigational and is being tested only in the SOTERIA Phase 2 trial.

Status: ClinicalTrials.gov lists the trial as not yet recruiting; Polaryx said on November 9, 2026 that its first US site had been activated to begin screening.

Results: none published in people.

Designations: FDA orphan drug for Krabbe disease (August 30, 2021), and Fast Track for Krabbe disease, announced by Polaryx on April 21, 2026.

Source: ClinicalTrials.gov NCT07740512; FDA orphan designation database; Polaryx releases, April 21 and November 9, 2026.

▸Who can join the PLX-200 SOTERIA trial for Krabbe disease?

Children aged 2 to 15 with genetically confirmed Krabbe disease whose symptoms and age at onset fit the type being studied.

Not eligible: any earlier stem cell transplant or gene therapy, breathing support other than CPAP or BiPAP during sleep, uncontrolled seizures, gallbladder disease, high liver tests or reduced kidney filtering.

Medicines not allowed: statins, repaglinide, dasabuvir, selexipag, pioglitazone and other fibrates.

Where: Polaryx names Boys Town National Research Hospital in Nebraska as its first site; ClinicalTrials.gov lists no sites yet.

Source: ClinicalTrials.gov NCT07740512; Polaryx release, November 9, 2026.

▸Can a child with Krabbe disease who had a stem cell transplant get PLX-200?

Not in SOTERIA. The trial excludes any child who has ever had a stem cell transplant or gene therapy, whenever it happened.

Expanded access: ClinicalTrials.gov shows no expanded access program, and Polaryx has not announced one.

Ask: the transplant or leukodystrophy team can say which other studies fit a child after transplant.

Source: ClinicalTrials.gov NCT07740512 and NCT04637282.

▸Is PLX-200 the same as gemfibrozil?

Yes. Polaryx describes PLX-200 as an oral compound made of gemfibrozil, prepared as a liquid for children.

Gemfibrozil tablets: FDA approved only for adults with high blood fats, and the label says safety and effectiveness in children have not been established.

Krabbe disease: no study in people has shown that gemfibrozil helps.

Ask: whether any medicine fits a child is a question for the child's specialist.

Source: Polaryx release, April 21, 2026; gemfibrozil tablets label (DailyMed); ClinicalTrials.gov NCT07740512.

▸When will PLX-200 results come out?

No date has been announced for Krabbe disease results.

Registry: estimated primary completion December 31, 2028 and study completion February 1, 2029.

Interim data: Polaryx plans early safety and biomarker updates and a 54-week look, without dates.

Source: ClinicalTrials.gov NCT07740512; Polaryx corporate presentation, November 2026.

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. ClinicalTrials.gov. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol). https://clinicaltrials.gov/study/NCT07740512
  2. ClinicalTrials.gov. Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3. https://clinicaltrials.gov/study/NCT04637282
  3. U.S. Food and Drug Administration · 2021-08-30. Search Orphan Drug Designations and Approvals: Gemfibrozil, treatment of Krabbe disease. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=834921
  4. Polaryx Therapeutics (GlobeNewswire, BioSpace copy) · 2026-11-09. Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200. https://www.biospace.com/press-releases/polaryx-therapeutics-activates-first-clinical-trial-site-for-soteria-phase-2-basket-trial-of-plx-200
  5. Polaryx Therapeutics · 2026-04-21. Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial. https://investors.polaryx.com/pr/polaryx-therapeutics-receives-us-fda-fast-track-designations-for-all-four-indications-to-be-evaluated-in-the-soteria-basket-trial
  6. Polaryx Therapeutics · 2026-08-25. Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial. https://investors.polaryx.com/pr/polaryx-therapeutics-advances-operational-readiness-for-soteria-phase-2-basket-trial
  7. Polaryx Therapeutics · 2026-02-03. Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium as Company Prepares for SOTERIA Trial Launch. https://investors.polaryx.com/pr/polaryx-to-present-latebreaker-data-related-to-soteria-at-the-22nd-annual-worldsymposium-as-company-prepares-for-soteria-trial-launch
  8. Polaryx Therapeutics · 2026-11. Polaryx Therapeutics Corporate Presentation, November 2026. https://storage.googleapis.com/vendorgroup-assets/site/f2ca1d02-b66c-41df-9ec1-d2bfc64b0a36/2026/11/02/6ae840dd899ca6383033b860/Polaryx%20Therapeutics%20Corporate%20Presentation_November.pdf
  9. Polaryx Therapeutics (PR Newswire) · 2021-08-30. Polaryx Therapeutics Announces FDA Grants Orphan Drug Designation for PLX-200 in GM2 Gangliosidoses. https://www.prnewswire.com/news-releases/polaryx-therapeutics-announces-fda-grants-orphan-drug-designation-for-plx-200-in-gm2-gangliosidoses-301364861.html
  10. Polaryx Therapeutics (PR Newswire) · 2018-02-26. Polaryx Therapeutics Received Orphan Drug Designation From the European Medicines Agency (EMA) for the Treatment of Neuronal Ceroid Lipofuscinosis With PLX-200. https://www.prnewswire.com/news-releases/polaryx-therapeutics-received-orphan-drug-designation-from-the-european-medicines-agency-ema-for-the-treatment-of-neuronal-ceroid-lipofuscinosis-with-plx-200-300604074.html
  11. Journal of Biological Chemistry 290(16):10309-10324 · 2015-04-17. Activation of peroxisome proliferator-activated receptor alpha induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders. https://pubmed.ncbi.nlm.nih.gov/25750174/
  12. Journal of Biological Chemistry 287(46):38922-38935 · 2012-11-09. Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor alpha: implications for late infantile Batten disease therapy. https://pubmed.ncbi.nlm.nih.gov/22989886/
  13. Orphanet Journal of Rare Diseases 12:113 · 2017-06-17. Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders. https://pubmed.ncbi.nlm.nih.gov/28623936/
  14. DailyMed, National Library of Medicine · 2024-11-08. DailyMed: GEMFIBROZIL tablet (Zydus Pharmaceuticals USA). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=556945e8-4100-4538-bcba-af5b2f13a7e8
  15. MedlinePlus Genetics, National Library of Medicine. Krabbe disease. https://medlineplus.gov/genetics/condition/krabbe-disease/

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow PLX-200 by email

We'll email you when the FDA acts on PLX-200 and when new trials for the condition you pick open. Unsubscribe anytime.

You'll get, for Krabbe Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site